Skip to content
Research/Cognitive Enhancement/Lumateperone

Lumateperone

Lumateperone is an atypical antipsychotic primarily used for the treatment of schizophrenia. It works by modulating serotonin, dopamine, and glutamate pathways, which are crucial for cognitive function and mood regulation. Its relevance to longevity and health optimization lies in its potential to improve mental health and cognitive function, which are critical components of overall well-being.

Intelligence Profile

Clinical Applications

Clinical Applications of Lumateperone

Lumateperone is primarily used in the treatment of several psychiatric conditions, with key applications in schizophrenia, major depressive disorder (MDD), and potential use in bipolar disorder and borderline personality disorder (BPD).

  1. Schizophrenia: Lumateperone has been studied for its efficacy in treating schizophrenia. While the specific study findings from NCT03817528 were not provided, it was undergoing evaluation in a Phase 2 trial before termination.

  2. Major Depressive Disorder (MDD): Lumateperone is explored as an adjunctive therapy for MDD. A pooled analysis of two randomized, placebo-controlled trials (PMID: 42455478) indicated it was well-tolerated. Another post hoc analysis (PMID: 42344568) found that lumateperone was effective in reducing anhedonia and other depressive symptoms when added to existing treatments.

  3. Bipolar Depression and Mania: There is limited evidence regarding bipolar disorder. A completed Phase 3 trial (NCT06462586) investigated lumateperone for acute bipolar mania, though specific results are not cited. Meta-analyses (PMID: 42331044 and PMID: 42283956) provide broader context on its comparative use with other antipsychotics in similar conditions.

  4. Borderline Personality Disorder (BPD): A double-blind, placebo-controlled study (PMID: 42384092) evaluated lumateperone for BPD treatment, suggesting potential benefits, but detailed outcome metrics are not specified.

  5. Psychotic Symptoms and Apathy: An ongoing Phase 3 trial (NCT06482554) examines its effect on apathy in patients with psychotic symptoms, indicating expanding therapeutic inquiries.

Overall, lumateperone is a versatile treatment option with evidence supporting its use primarily in schizophrenia and MDD. Its safety and efficacy in other conditions are still under review, and ongoing research may further clarify these roles.

Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice.

Free account required

Clinical data requires a free AXIFI account to access clinical data, safety profiles, and research papers.